Compounding pharmacies are crimping sales of Novo Nordisk's obesity drug Wegovy by making what are essentially copies of the ...

COPENHAGEN (Reuters) -Obesity drugmaker Novo Nordisk on Tuesday cut its full-year sales and operating profit forecasts for ...

Danish drugmaker Novo Nordisk's stock was down nearly 20% in premarket trading Tuesday morning after the company cut its ...

Novo Nordisk’s plummet is a warning for backers who’ve crowded into a relatively small group of very large stocks.

With over 40% of Americans classified as obese, the need for effective long-term weight-loss solutions is greater than ever. Obesity can lead to serious health issues like diabetes, heart disease, ...

One of the more popular stocks in the pharmaceutical sector of late got the cold shoulder from investors on Tuesday. Eli Lilly ( LLY -5.50%) closed today's trading session down by almost 6% in value, ...

Novo Nordisk stock (NVO) (DK:NOVO.B) slumped 21.83% to fall to a new three-year low. It was the stock's worst daily loss since a 26.15% fall on Oct. 19, 1987. It's fallen 24.77% over the past two days ...

Novo, which became Europe’s most valuable listed company following the launch of Wegovy in 2021, is now facing a reckoning as ...

The pharmaceutical giant cut its guidance and said U.S. sales of Ozempic grew more slowly.

Novo Nordisk said it expects weaker sales growth of its popular weight-loss drug Wegovy due to competition from copycat drugs ...

Knockoff copies of Novo’s weight loss medicine Wegovy have held back sales and put the drugmaker on the back foot in its ...

Novo Nordisk faces a significant market value drop amid competition and leadership changes. Maziar Mike Doustdar has been ...